News
CYCCP
6.77
0.00%
0.00
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced t...
GlobeNewswire · 6d ago
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Pub...
GlobeNewswire · 05/11 20:05
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce firs...
GlobeNewswire · 05/04 13:15
BRIEF-Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140
reuters.com · 04/19 13:19
Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Cyc140 In Patients With Advanced Solid Tumors And Lymphomas
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - BERKELEY HEIGHTS, N.J., April 19, 2022
Benzinga · 04/19 13:17
Cyclacel Pharmaceuticals Doses First Patient in Phase 1/2 Trial of Potential Treatment for Advanced Solid Tumors
MT Newswires · 04/19 11:56
We're Keeping An Eye On Cyclacel Pharmaceuticals' (NASDAQ:CYCC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 04/15 12:33
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 And Synergizes With Venetoclax In Chronic Lymphocytic Leukemia
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today
Benzinga · 04/12 11:06
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fo...
GlobeNewswire · 03/22 11:00
Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced ...
GlobeNewswire · 03/09 12:00
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced t...
GlobeNewswire · 02/07 12:00
BRIEF-Cyclacel Pharmaceuticals Announces Key Business Objectives For 2022
reuters.com · 01/06 12:42
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced t...
GlobeNewswire · 12/23/2021 12:00
BRIEF-Cyclacel Pharma Reports Q3 2021 Financial Results
reuters.com · 11/10/2021 22:35
Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -- Cash Runway to Early 2023 -- Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc...
GlobeNewswire · 11/10/2021 21:05
Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Fadraciclib In Patients With Leukemias Or Myelodysplastic Syndromes
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology,
Benzinga · 11/05/2021 13:44
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed StudyBERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CY...
GlobeNewswire · 11/05/2021 13:41
Hedge Funds Have Never Been This Bullish On Cyclacel Pharmaceuticals Inc (CYCC)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of June 30th. The r...
Insider Monkey · 10/04/2021 13:00
BRIEF-Cyclacel Pharmaceuticals Inc - May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 Million From Time To Time
reuters.com · 08/12/2021 21:38
BRIEF-Cyclacel Pharmaceuticals Reports Q2 Financial Results
reuters.com · 08/11/2021 21:07
More
Webull provides a variety of real-time CYCCP stock news. You can receive the latest news about Cyclacel Phar Pr through multiple platforms. This information may help you make smarter investment decisions.
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.